Mabs directed against the cell surface antigens, CD19 and CD22 conjugated to deglycosylated ricin A chain (dgRTA) have been tested in patients with non-Hodgkin's lymphoma (NHL), but not in ...

“CLN-978 is the only CD19-targeting T cell engager advancing a global regulatory development plan that includes a US FDA-cleared IND. Delivering the potency of T cell redirecting therapy with the ...